Granted Patent
B2
US 12,447,209 · App. 17/822,054 · Granted Oct 21, 2025
Combination of vaccination and inhibition of the PD-1 pathway
Inventors:
Mariola Fotin-Mleczek (Sindelfingen, DE); Karl-Josef Kallen (Konigsdorf, DE); Jochen Probst (Wolfschlugen, DE)
Assignee:
Cure Vac SE
A61K39/39558A61K39/0005A61K39/0011A61K39/39A61K39/3955C07K16/2803C07K16/2818A61K2039/505A61K2039/53A61K2039/55516C07K2317/76Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
Claims (37)
1. A method of treating a subject having a cancer comprising administering to the subject:
(i) an immunogenic composition comprising mRNA encoding at least one epitope of a tumour-specific antigen (TSA), wherein said mRNA comprises a 5′ Cap and a Poly-A sequence of 25 to 400 consecutive adenosine nucleotides, wherein said mRNA is provided in complex with a cationic or polycationic carrier; and
(ii) a PD-1 pathway inhibitor, said PD-1 pathway inhibitor comprising an antagonistic antibody that binds to PD-1.
2. The method of claim 1 , wherein the subject has previously been administered a PD-1 pathway inhibitor.
3. The method of claim 1 , wherein the PD-1 pathway inhibitor is administered before said immunogenic composition.
4. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered sequentially.
5. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered concurrently.
6. The method of claim 1 , wherein the subject has a melanoma.
7. The method of claim 1 , wherein the subject has a metastatic solid tumor.
8. The method of claim 1 , wherein the PD-1 pathway inhibitor is administered intravenously.
9. The method of claim 8 , wherein the immunogenic composition is administered subcutaneously, intravenously, intradermally or intramuscularly.
10. The method of claim 9 , wherein the immunogenic composition is administered intramuscularly.
11. The method of claim 8 , wherein at least one epitope of the TSA comprises a tumour specific mutation.
12. The method of claim 8 , wherein the immunogenic composition comprises mRNA encoding at least two epitopes of the TSA.
13. The method of claim 8 , wherein the immunogenic composition comprises mRNA encoding at least two epitopes from different TSAs.
14. The method of claim 13 , wherein at least two epitopes of the different TSAs comprise tumour specific mutations.
15. The method of claim 13 , wherein at least two epitopes of the different TSAs are encoded on the same mRNA molecule.
16. The method of claim 13 , wherein the immunogenic composition comprises mRNA encoding at least three, four, five or more epitopes from different TSAs.
17. The method of claim 16 , wherein the epitopes of the different TSAs are encoded on the same mRNA molecule.
18. The method of claim 16 , wherein the immunogenic composition is administered intramuscularly.
19. The method of claim 18 , wherein the mRNA comprises a modification of a nucleobase.
20. The method of claim 18 , wherein the carrier comprises a cationic or polycationic lipid.
21. The method of claim 1 , wherein the antagonistic antibody that binds to PD-1 is a bispecific antibody.
22. The method of claim 1 , wherein the antagonistic antibody that binds to PD-1 is MDX-1106, CT-011 or MK-3475.
23. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is MDX-1106.
24. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is CT-011.
25. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is MK-3475.
26. The method of claim 25 , wherein the PD-1 pathway inhibitor is administered intravenously.
27. The method of claim 26 , wherein the immunogenic composition is administered subcutaneously, intravenously, intradermally or intramuscularly.
28. The method of claim 27 , wherein the immunogenic composition is administered intramuscularly.
29. The method of claim 28 , wherein at least one epitope of the TSA comprises a tumour specific mutation.
30. The method of claim 29 , wherein the carrier comprises a cationic or polycationic lipid.
31. The method of claim 29 , wherein the subject has a melanoma.
32. The method of claim 29 , wherein the subject has a metastatic solid tumor.
33. The method of claim 29 , wherein the subject has non-small lung cancer (NSCLC).
34. The method of claim 29 , wherein the subject has a renal carcinoma.
35. The method of claim 29 , wherein the subject has a bladder cancer.
Assignments (1)
Priority Claims (1)
WO PCT/EP2013/000526
· Feb 22, 2013
· international
Continuity (4)
Continuation
14769720
References Cited (400)
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8168757B2
· Finnefrock et al.
· 2012
[cited by applicant]
US 8217016B2
· Hoerr et al.
· 2012
[cited by applicant]
US 8345509B2
· Vu et al.
· 2013
[cited by applicant]
US 8383340B2
· Ketterer et al.
· 2013
[cited by applicant]
US 8445663B2
· Sällberg et al.
· 2013
[cited by applicant]
US 8703906B2
· Baumhof et al.
· 2014
[cited by applicant]
US 8728474B2
· Honjo et al.
· 2014
[cited by applicant]
US 8968746B2
· Baumhof et al.
· 2015
[cited by applicant]
US 9155788B2
· Hoerr et al.
· 2015
[cited by applicant]
US 9974845B2
· Fotin-Mleczek et al.
· 2018
[cited by applicant]
US 20050250723A1
· Hoerr et al.
· 2005
[cited by applicant]
US 20060188490A1
· Hoerr et al.
· 2006
[cited by applicant]
US 20080025944A1
· Hoerr et al.
· 2008
[cited by applicant]
US 20080267873A1
· Hoerr et al.
· 2008
[cited by applicant]
US 20090324584A1
· Hoerr et al.
· 2009
[cited by applicant]
US 20100035973A1
· Walker
· 2010
[cited by applicant]
US 20100040614A1
· Ahmed et al.
· 2010
[cited by applicant]
US 20100076060A1
· Sullenger et al.
· 2010
[cited by applicant]
US 20100203076A1
· Fotin-Mleczek et al.
· 2010
[cited by applicant]
US 20100239608A1
· Von Der Mülbe et al.
· 2010
[cited by applicant]
US 20100291156A1
· Barner et al.
· 2010
[cited by applicant]
US 20100303851A1
· Hoerr et al.
· 2010
[cited by applicant]
US 20100305196A1
· Probst et al.
· 2010
[cited by applicant]
US 20110053829A1
· Baumhof et al.
· 2011
[cited by applicant]
US 20110077287A1
· Von Der Mülbe et al.
· 2011
[cited by applicant]
US 20110269950A1
· Von Der Mülbe et al.
· 2011
[cited by applicant]
US 20110311472A1
· Hoerr et al.
· 2011
[cited by applicant]
US 20120009221A1
· Hoerr et al.
· 2012
[cited by applicant]
US 20120213818A1
· Hoerr et al.
· 2012
[cited by applicant]
US 20120258046A1
· Mutzke
· 2012
[cited by applicant]
US 20130195867A1
· Hoerr et al.
· 2013
[cited by applicant]
US 20130273001A1
· Hoerr et al.
· 2013
[cited by applicant]
US 20130295043A1
· Kallen et al.
· 2013
[cited by applicant]
US 20150037326A1
· Butler-Ransohoff et al.
· 2015
[cited by applicant]
US 20150118183A1
· Baumhof
· 2015
[cited by applicant]
US 20150118264A1
· Baumhof et al.
· 2015
[cited by applicant]
US 20150258214A1
· Baumhof et al.
· 2015
[cited by applicant]
US 20150306249A1
· Baumhof et al.
· 2015
[cited by applicant]
US 20160166668A1
· Kallen et al.
· 2016
[cited by applicant]
US 20160168227A1
· Kallen et al.
· 2016
[cited by applicant]
US 20160206719A1
· Fotin-Mleczek et al.
· 2016
[cited by applicant]
US 20170326225A1
· Rauch et al.
· 2017
[cited by applicant]
US 20180126003A1
· Hoerr
· 2018
[cited by applicant]
US 20180148727A1
· Grund et al.
· 2018
[cited by applicant]
US 20180208957A1
· Roos et al.
· 2018
[cited by applicant]
US 20180296663A1
· Hipp et al.
· 2018
[cited by applicant]
US 20180312545A1
· Baumhof et al.
· 2018
[cited by applicant]
US 20180371392A1
· Mayer et al.
· 2018
[cited by applicant]
US 20190017100A1
· Wochner et al.
· 2019
[cited by applicant]
US 20190024096A1
· Schmid et al.
· 2019
[cited by applicant]
US 20190049414A1
· Wochner et al.
· 2019
[cited by applicant]
US 20190177714A1
· Kunze et al.
· 2019
[cited by applicant]
US 20190185859A1
· Fotin-Mleczek et al.
· 2019
[cited by applicant]
US 20190194760A1
· Koch et al.
· 2019
[cited by applicant]
US 20190225971A1
· Williams
· 2019
[cited by applicant]
US 20190336608A1
· Baumhof et al.
· 2019
[cited by applicant]
US 20190336611A1
· Baumhof et al.
· 2019
[cited by applicant]
US 20190343942A1
· Fotin-Mleczek et al.
· 2019
[cited by applicant]
US 20190381180A1
· Baumhof et al.
· 2019
[cited by applicant]
US 20200085852A1
· Fotin-Mleczek
· 2020
[cited by applicant]
US 20200085944A1
· Heidenreich et al.
· 2020
[cited by applicant]
US 20200163878A1
· Baumhof et al.
· 2020
[cited by applicant]
CN 104987421A
· 2015
[cited by applicant]
CN 105793287A
· 2016
[cited by applicant]
EP 1392341
· 2005
[cited by applicant]
EP 1604688
· 2010
[cited by applicant]
EP 2958588
· 2017
[cited by applicant]
EP 3292873
· 2018
[cited by applicant]
TW 201625684A
· 2016
[cited by applicant]
WO WO1999042585
· 1999
[cited by applicant]
WO WO2002066044
· 2002
[cited by applicant]
WO WO2002086063
· 2002
[cited by applicant]
WO WO2002086083
· 2002
[cited by applicant]
WO WO2002098443
· 2002
[cited by applicant]
WO WO2004004743
· 2004
[cited by applicant]
WO WO2006044923
· 2006
[cited by applicant]
WO WO2006121810
· 2006
[cited by applicant]
WO WO2006133396
· 2006
[cited by applicant]
WO WO2007005874
· 2007
[cited by applicant]
WO WO2008011344
· 2008
[cited by applicant]
WO WO2008083174
· 2008
[cited by applicant]
WO WO2008083949
· 2008
[cited by applicant]
WO WO2008085562
· 2008
[cited by applicant]
WO WO2008156712
· 2008
[cited by applicant]
WO WO2009046738
· 2009
[cited by applicant]
WO WO2009114335
· 2009
[cited by applicant]
WO WO2010036959
· 2010
[cited by applicant]
WO WO2010037408
· 2010
[cited by applicant]
WO WO2010063011
· 2010
[cited by applicant]
WO WO2011066389
· 2011
[cited by applicant]
WO WO2012006369
· 2011
[cited by applicant]
WO WO2011143656
· 2011
[cited by applicant]
WO WO2012006634
· 2012
[cited by applicant]
WO WO2012062218
· 2012
[cited by applicant]
WO WO2013143555
· 2013
[cited by applicant]
WO WO2013143683
· 2013
[cited by applicant]
WO WO2014127917
· 2014
[cited by applicant]
WO WO2015042246
· 2015
[cited by applicant]
WO WO2015048312
· 2015
[cited by applicant]
WO WO2015135558
· 2015
[cited by applicant]
WO WO2015200119
· 2015
[cited by applicant]
WO WO2016180034
· 2016
[cited by applicant]
WO WO2017020026
· 2017
[cited by applicant]
WO WO2017025498
· 2017
[cited by applicant]
WO WO2017137095
· 2017
[cited by applicant]
WO WO2017140905
· 2017
[cited by applicant]
WO WO2017191258
· 2017
[cited by applicant]
WO WO2018078053
· 2018
[cited by applicant]
WO WO2018096179
· 2018
[cited by applicant]
WO WO2018172556
· 2018
[cited by applicant]
WO WO2018211038
· 2018
[cited by applicant]
WO WO2019038332
· 2019
[cited by applicant]
WO WO2019077001
· 2019
[cited by applicant]
WO WO2019092153
· 2019
[cited by applicant]
WO WO2019122371
· 2019
[cited by applicant]
Office Communication issued in Chinese Application No. 201880015304.1, mailed Jan. 11, 2023. English translation and search report appended.
[cited by applicant]
Berrien-Elliot et al., “Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance,” Cancer Res 73:605-616, 2012.
[cited by applicant]
Carralot et al., “Polarization of immunity induced by direct injection of naked sequence- stabilized mRNA vaccines,” Cell Mol Life Sci 61:2418-2424, 2004.
[cited by applicant]
Chen et al., “Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1,” Clin Cancer Res 18:6580-6587, 2012.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01585194, first posted Apr. 25, 2012, updated Nov. 4, 2019.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01621490, first posted Jun. 18, 2012, updated Dec. 3, 2019.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01024231, first posted Dec. 2, 2009, updated Mar. 11, 2020.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01472081, first posted Nov. 16, 2011, updated Mar. 11, 2020.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01714739, first posted Oct. 26, 2012, updated Mar. 18, 2020.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01658878, first posted Aug. 7, 2012, updated Mar. 25, 2020.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01454102, first posted Oct. 18, 2011, updated Mar. 5, 2020.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrails.gov Identifier: NCT01592370, first posted May 7, 2012, updated Nov. 19, 2019.
[cited by applicant]
Clinical trial record for the trial having ClinicalTrials.gov Identifier: NCT01176474, first posted Aug. 6, 2010, updated Mar. 4, 2020.
[cited by applicant]
Conry et al., “Characterization of a Messenger RNA Polynucleotide Vaccine Vector,” Cancer Research 55:1397-1400, 1995.
[cited by applicant]
Declaration of Dr. Mariola Fotin-Mleczek, dated Apr. 16, 2021, filed in Opposition Proceedings against EP 2958588 (9 pages).
[cited by applicant]
Declaration of Dr. Regina Heidenreich, dated Apr. 16, 2021, filed in Opposition Proceedings against EP 2958588 (11 pages).
[cited by applicant]
Declaration of Dr. Ulrike Gnad-Vogt, dated Apr. 16, 2021, filed in Opposition Proceedings against EP 2958588 (10 pages).
[cited by applicant]
Declaration of Dr. Ulrike Gnad-Vogt, dated Nov. 4, 2022, filed in Opposition Proceedings against EP 3292873 (10 pages).
[cited by applicant]
Declaration of Prof. Jonathan M. Bramson, dated Apr. 15, 2020, filed in Opposition Proceedings against EP 2958588 (56 pages).
[cited by applicant]
Gadiot et al., “Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma,” Cancer 117:2192-2201, 2011.
[cited by applicant]
Geall et al., “Nonviral delivery of self-amplifying RNA vaccines,” Proc Natl Acad Sci USA 109:14604-14609, 2012.
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated Dec. 6, 2021 (7 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of ModernaTx, Inc., dated Dec. 7, 2021 (49 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of Strawman Limited, dated Dec. 7, 2021 (41 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of Dr. Georg Schnappauf, dated Dec. 7, 2021 (32 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of eTheRNA immunotherapies NV, dated Dec. 7, 2021 (10 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 2958588, Submission of Merck Sharpe & Dohme Corp., dated Dec. 7, 2021 (20 pages).
[cited by applicant]
Grounds of Appeal filed in the Opposition Proceedings of EP 3292873, Submission of Proprietor, dated Apr. 28, 2023 (37 pages).
[cited by applicant]
Hoerr et al., “In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies,” Eur J Immunol 30:1-7, 2000.
[cited by applicant]
Interlocutory Decision of the Opposition Division, in the Opposition Proceedings of EP 2958588, dated Jul. 28, 2021 (22 pages).
[cited by applicant]
Interlocutory Decision of the Opposition Division, in the Opposition Proceedings of EP 3292873, dated Dec. 22, 2022 (34 pages).
[cited by applicant]
Knutson & Disis, “Tumor antigen-specific T helper cells in cancer immunity and immunotherapy,” Cancer Immunol Immunother 54:721-728, 2005.
[cited by applicant]
Kreiter et al., “Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity,” Cancer Research 70:9031-9040, 2010.
[cited by applicant]
Kuhn et al., “mRNA as a versatile tool for exogenous protein expression,” Current Gene Therapy 12:347-361, 2012.
[cited by applicant]
Lin et al., “Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma,” Cancer Biology & Therapy 20:666-679, 2018.
[cited by applicant]
Mangsbo et al., “Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy,” J Immunother 33:225-235, 2010.
[cited by applicant]
McGray et al., “Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients,” OncoImmuno…
[cited by applicant]
Mockey et al., “mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes,” Cancer Gene Therapy 14:802-814, 2007.
[cited by applicant]
Notice of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of ModernaTX, Inc., dated May 22, 2018 (47 pages).
[cited by applicant]
Notice of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of Dr. Georg Schnappauf, dated May 22, 2018 (35 pages).
[cited by applicant]
Notice of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of Strawman Limited, dated May 23, 2018 (62 pages).
[cited by applicant]
Notice of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of Merck, Sharp, & Dohme Corp., dated May 23, 2018 (13 pages).
[cited by applicant]
Notice of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of eTheRNA immunotherapies NV, dated May 23, 2018 (23 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 2958588, Submission of Merck, Sharp, & Dohme Corp., dated Apr. 15, 2020 (6 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 2958588, Submission of ModernaTX Inc., dated Apr. 15, 2020 (12 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 2958588, Submission of Strawman Limited, dated Apr. 15, 2020 (40 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 2958588, Submission of Dr. Georg Schnappauf, dated Apr. 15, 2020 (20 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 2958588, Submission of ModernaTX Inc., dated Apr. 16, 2021 (11 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 3292873, Submission of Strawman Limited, dated Sep. 7, 2022 (48 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 3292873, Submission of BioNTech RNA Pharmaceuticals GmbH, dated Sep. 8, 2022 (30 pages).
[cited by applicant]
Opponent's arguments filed in the Opposition Proceedings of EP 3292873, Submission of James Poole Limited, dated Sep. 8, 2022 (33 pages).
[cited by applicant]
Opponent's Further Reply to Proprietor's Grounds of Appeal filed in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of Merck Sharpe & Dohme Corp., dated Apr. 11, 2023 (14 pages).
[cited by applicant]
Opponent's Reply to Proprietor's Grounds of Appeal filed in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of Strawman Limited, dated Apr. 22, 2022 (9 pages).
[cited by applicant]
Opponent's Reply to Proprietor's Grounds of Appeal filed in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of Dr. Georg Schnappauf, dated Apr. 22, 2022 (5 pages).
[cited by applicant]
Opponent's Reply to Proprietor's Grounds of Appeal filed in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of Merck Sharpe & Dohme Corp., dated Apr. 25, 2022 (3 pages).
[cited by applicant]
Opponent's Reply to Proprietor's Grounds of Appeal filed in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of ModernaTx, Inc., dated Apr. 25, 2022 (8 pages).
[cited by applicant]
Pan et al., “PD-1 antibody ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice,” American Journal of Transplantation 21:503-514, 2020.
[cited by applicant]
Pardoll et al., “Immunology beats cancer: a blueprint for successful translation,” Nature Immunology 13:1129-1132, 2012.
[cited by applicant]
Preliminary Opinion of the Opposition Division, in the Opposition Proceedings of EP 2958588, dated May 22, 2019 (16 pages).
[cited by applicant]
Preliminary Opinion of the Opposition Division, in the Opposition Proceedings of EP 3292873, dated Dec. 7, 2020 (17 pages).
[cited by applicant]
Proprietor's arguments filed in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated Apr. 15, 2020 (9 pages).
[cited by applicant]
Proprietor's arguments filed in the Opposition Proceedings of EP 3292873, Submission of Proprietor, dated Sep. 8, 2022 (4 pages).
[cited by applicant]
Proprietor's Reply to Opponents' Grounds of Appeal led in Appeal T 1639/21-3.3.04 in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated Apr. 25, 2022 (50 pages).
[cited by applicant]
Proprietor's Reply to the Opponent's Submissions of Apr. 16, 2021, filed in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated May 19, 2021 (6 pages).
[cited by applicant]
Proprietor's Reply to the Opponent's Submissions of Sep. 2022, filed in the Opposition Proceedings of EP 3292873, Submission of Proprietor, dated Nov. 4, 2022 (27 pages).
[cited by applicant]
Proprietor's Reply to the Opponents' Notices of Opposition, filed in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated Jan. 2, 2019 (34 pages).
[cited by applicant]
Proprietor's Reply to the Opponents' Submissions of Apr. 15, 2020, filed in the Opposition Proceedings of EP 2958588, Submission of Proprietor, dated Apr. 16, 2021 (26 pages).
[cited by applicant]
Pulendran & Ahmed, “Immunological mechanisms of vaccination,” Nat Immunol., 12:509-517, 2011.
[cited by applicant]
Response filed by Applicant in the prosecution of EP 14706481.0, dated Dec. 2, 2016 (6 pages).
[cited by applicant]
Response filed by Applicant in the prosecution of EP 14706481.0, dated Feb. 23, 2017 (4 pages).
[cited by applicant]
Rittig et al., “Intradermal Vaccinations with RNA Coding for TAA Generated CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients,” Molecular Therapy 19:990-999, 2011.
[cited by applicant]
Romero, “Current State of Vaccine Therapies in Non-Small Lung Cancer,” Clinical Lung Cancer 9:S28-S36, 2008.
[cited by applicant]
Rosenberg et al., “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine 10:909-915, 2004.
[cited by applicant]
Sahin et al, “mRNA-based therapeutics-developing a new class of drugs,” Nature Reviews Drug Discovery 13:759-780, 2014.
[cited by applicant]
Sahin et al., “Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer,” Nature 547:222-226 and supplemental online content, 2017.
[cited by applicant]
Schardt, “Der Einsatz von Immuncheckpoint-Inhibitoren im onkologischen Alltag,” Z.Rheumatol., 79:809-917, 2020. (English language machine translation appended).
[cited by applicant]
Schlom et al., “Therapeutic Cancer Vaccines: Current Status and Moving Forward,” J Natl Cancer Inst 104:599-613, 2012.
[cited by applicant]
Shrikant & Mescher, “Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness,” The Journal of Immunology 162:2858-2866, 199…
[cited by applicant]
Taube et al., “Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape,” Science Translational Medicine, 4:127ra37, pp. 1-10,…
[cited by applicant]
Van Lint et al., “mRNA—From a chemical blueprint for protein production to an off-the-shelf therapeutic,” Human Vaccines & Immunotherapeutics 9:265-274, 2013.
[cited by applicant]
Van Lint et al., “Preclinical evaluation of TriMix and antigen mRNA-based antitumour therapy,” Cancer Res 72:1661-1671, 2012.
[cited by applicant]
Weide et al., “Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients,” J Immunother 32:498-507, 2009.
[cited by applicant]
Wolchok et al., “Immune Regulatory Antibodies. Are They the Next Advance?” The Cancer Journal 16:311-317, 2010.
[cited by applicant]
Wolchok et al., “Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients,” N Engl J Med 369:122-133, 2013.
[cited by applicant]
Yu et al., “Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model,” Clin Cancer Res 16:6019-6028, 2010.
[cited by applicant]
Zhou et al., “RNA Melanoma Vaccine: Induction of Antitumor Immunity by Human Glycoprotein 100 mRNA Immunization,” Human Gene Therapy 10:2719-2724, 1999.
[cited by applicant]
Barber et al. “Restoring function in exhausted CDS T cells during chronic viral infection”,
[cited by applicant]
Beck et al., 6
[cited by applicant]
Berenbaum, “Synergy, additivism and antagonism in immunosuppression,”
[cited by applicant]
Blank et al. “Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,”
[cited by applicant]
Brahmer et al. “Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,”
[cited by applicant]
Brahmer et al., “Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer,”
[cited by applicant]
Burova et al., “Combined treatment with anti-LAG-3 and anti-PD-1 fully human monoclonal antibodies inhibits tumor growth in immunocompetent double humanized LAG-3/PD-1 mice,”
[cited by applicant]
Butte et al., “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses”,
[cited by applicant]
Clinical trial profile of the trial having ClinicalTrials.gov Identifier: NCT01176461, including the presentation of data as Abstract 8582; presented at the American Society of Clinical Oncology ASCO in 2012.
[cited by applicant]
Clinical trial profile of the trial having ClinicalTrials.gov Identifier: NCT01176474, 2013.
[cited by applicant]
Curran et al. “PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumours,”
[cited by applicant]
Dai et al., “PD-1/PD-L1 blockade can enhance HIV-1 gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines,”
[cited by applicant]
Dollins et al., “Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer”,
[cited by applicant]
DrugBank Listing for Pembrolizumab, accessed on Jan. 18, 2018 at http://www.drugbank.ca/drugs/DB09037; 6 pages.
[cited by applicant]
Duraiswamy et al., “Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T cell rejection function in tumors,”
[cited by applicant]
Editorial Policies of the American Association for Cancer Research.
[cited by applicant]
Evans et al., “Engagement of OX40 enhances antigen-specific CD4+ T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4”,
[cited by applicant]
Experimental Details OVA Experiments filed in Opposition of EP 3292873 Proprietor Response dated Aug. 28, 2020.
[cited by applicant]
Experimental Details Pentatope Experiments filed in Opposition of EP 3292873 Proprietor Response dated Aug. 28, 2020.
[cited by applicant]
Fleeton et al., “Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus”,
[cited by applicant]
Fotin-Mleczek et al., “Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect,”
[cited by applicant]
Fotin-Mleczek et al., “Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity,”
[cited by applicant]
Foy et al., “Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice,” PLoS ONE, e0150084, 2016.
[cited by applicant]
Gilboa, “The promise of cancer vaccines”,
[cited by applicant]
Goding et al., “Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors better with more,”
[cited by applicant]
Goding et al., “Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma,” J. Immunol., 190:4899-4909, 2013.
[cited by applicant]
Grunwitz et al., “HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory,”
[cited by applicant]
Ha et al., “Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection,”
[cited by applicant]
Hobo et al., “Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation,”
[cited by applicant]
Hodi et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,”
[cited by applicant]
Hoerr, Abstract OP 57, “Stabilized Messenger RNA (RNActive™) as a Tool for Innovative Gene Delivery,” presented at the BioStar 2006 2nd International Congress on Regenerative Biology and ICBN 2006 2nd International Cong…
[cited by applicant]
Huang et al., “LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model,” Oncotarget, 6:27359-27377, 2015.
[cited by applicant]
Hung et al., “DNA vaccines for cervical cancer: from bench to bedside”,
[cited by applicant]
Iclozan and Gabrilovich. “Recent advances in immunotherapy of lung cancer,”
[cited by applicant]
International Search Report issued in corresponding PCT Application No. PCT/EP2014/000659, mailed on Jul. 11, 2014.
[cited by applicant]
Jensen et al., “Signaling through OX40 enhances antitumor immunity”,
[cited by applicant]
Kleffel et al., “Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth,” Cell 162:1242-1256, 2015.
[cited by applicant]
Kreiter et al., “Tumor vaccination using messenger RNA: prospects of a future therapy”,
[cited by applicant]
La Motte-Mohs et al., American Association for Cancer Research Annual Meeting, poster 3217, 2016.
[cited by applicant]
Li et al., “Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors,”
[cited by applicant]
Li et al., “Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic Prostate Tumor Associated Antigen Gene Modified Tumor Cell and Blockade of B7-H1”,
[cited by applicant]
Linhares et al., “Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling,” Scientific Reports 9:11472, 2019.
[cited by applicant]
Lipson et al., “Durable cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody,”
[cited by applicant]
Liu et al., “The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine”,
[cited by applicant]
Lote et al., “PD-1 and PD-L1 blockade in gastrointestinal malignancies,” Cancer Treatment Reviews, 41:893-903, 2015.
[cited by applicant]
Mackensen, “Peptide and RNA-based vaccines for the treatment of cancer,”
[cited by applicant]
Mahoney et al., “Combination cancer immunotherapy and new immunomodulatory targets,”
[cited by applicant]
Martinon et al., “Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA,”
[cited by applicant]
Matsuzaki et al., “Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer,” PNAS, 107:7875-7880, 2010.
[cited by applicant]
Melero et al. “Palettes of vaccines and 2009 immunostimulatory monoclonal antibodies for combination,”
[cited by applicant]
Melero et al., “Agonist antibodies to TNFR molecules that costimulate T and NK cells”,
[cited by applicant]
Mkrtichyan et al., “Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms,”
[cited by applicant]
Monie et al., “Modification of Dendritic Cells to Enhance Cancer Vaccine Potency”, Targeted Cancer Immune Therapy. Springer, New York, NY, pp. 133-157, 2009.
[cited by applicant]
Murata et al., “OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ TCell Tolerance to an Endogenous Tumor Antigen”,
[cited by applicant]
NCI Drug Dictionary, Durvalumab, collected May 27, 2018.
[cited by applicant]
Notice of Opposition issued in corresponding European Patent No. 3116535, submitted on May 7, 2020.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/890,413, mailed on Apr. 11, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 14/769,720, mailed on Jun. 12, 2017.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 14/769,720, mailed on Sep. 14, 2017.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 14/769,720, mailed on Jan. 24, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/091,060, mailed on Feb. 9, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/091,060, mailed on Jun. 14, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/890,413, mailed on Aug. 8, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/890,736, mailed on Dec. 13, 2018.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/890,736, mailed on May 1, 2019.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 15/890,736, mailed on Aug. 21, 2019.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 16/555,586, mailed on Jan. 13, 2022.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 16/555,586, mailed on Apr. 20, 2022.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 16/555,586, mailed on May 11, 2022.
[cited by applicant]
Office Communication issued in corresponding U.S. Appl. No. 16/555,586, mailed on May 23, 2022.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 16/494,422, mailed Jul. 24, 2020.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 16/494,422, mailed Feb. 5, 2021.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 16/494,422, mailed Sep. 10, 2021.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 16/494,422, mailed Mar. 23, 2022.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 16/494,422, mailed Oct. 21, 2022.
[cited by applicant]
OMIM Entry 605402, creation date Nov. 14, 2000.
[cited by applicant]
OMIM Entry PD-1 *600244, 1994.
[cited by applicant]
Omori et al. “Effects of interferon-a-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors,”
[cited by applicant]
Opposition of EP 3292873, Notice from BioNTech dated, Jan. 31, 2020.
[cited by applicant]
Opposition of EP 3292873, Notice from eTheRNA dated, Feb. 3, 2020.
[cited by applicant]
Opposition of EP 3292873, Notice from James Poole, dated Feb. 3, 2020.
[cited by applicant]
Opposition of EP 3292873, Notice from Merck, dated Jan. 31, 2020.
[cited by applicant]
Opposition of EP 3292873, Notice from Pfizer, dated Feb. 3, 2020.
[cited by applicant]
Opposition of EP 3292873, Notice from Stawman, dated Jan. 31, 2020.
[cited by applicant]
Opposition of EP 3292873, Proprietor Response, dated Aug. 28, 2020.
[cited by applicant]
Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,”
[cited by applicant]
Pascolo, “Vaccination with Messenger RNA (mRNA)”, Handbook Experimental Pharmacology 183:221-235, 2008.
[cited by applicant]
Pascolo, “Vaccination with Messenger RNA, Methods in Molecular Medicine,” 127:23-40, 2006.
[cited by applicant]
Patentee submission in EP 3 292 873 dated Jul. 9, 2018.
[cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/EP2018/056774, mailed Apr. 13, 2018.
[cited by applicant]
PCT Search Report and Written Opinion issued in International Application No. PCT/US2014/000461, mailed Jun. 5, 2014.
[cited by applicant]
Pilon-Thomas et al., “Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma”,
[cited by applicant]
Postow et al., “Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy,”
[cited by applicant]
Product Sheet Anti PD-1.
[cited by applicant]
Qian et al., “Active Vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma”,
[cited by applicant]
Redmond et al., “Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist”,
[cited by applicant]
Ribas, “Tumor immunotherapy directed at PD-1”,
[cited by applicant]
Rosenblatt et al. “CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Ceil Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma,”
[cited by applicant]
Rosenblatt et al., “PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dend ritic cell/myeloma fusion vaccine,”
[cited by applicant]
Rossi et al., “Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity,”
[cited by applicant]
Salek-Ardakani et al., “Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection”,
[cited by applicant]
Scheel et al., Final program for Society for Immunotherapy of Cancer (SITC) 26th annual meeting, pp. 54-55, Nov. 4-6, 2011.
[cited by applicant]
Schlake et al., “Developing mRNA-vaccine technologies”
[cited by applicant]
Schurer et al., “A universal method to produce in vitro transcripts with homogeneous 3′ ends”,
[cited by applicant]
Sharma and Allison, “The future of immune checkpoint therapy,”
[cited by applicant]
Sharma et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,” Cell, 168:707-723, 2017.
[cited by applicant]
Sierro et al., “Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity,”
[cited by applicant]
Simes et al., Textual representation of the lecture of Stephen Simes, Biosante Pharmaceuticals Inc. at Jefferies Global Healthcare Conference, Jun. 6, 2012.
[cited by applicant]
Slingluff, “The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?”
[cited by applicant]
Soares et al., “Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer.” In: Proceedings of the AACR Special Con…
[cited by applicant]
Song et al., “Enhancement of Vaccine-induced Primary and Memory CDS+ Tcell Responses by Soluble PD-1,”
[cited by applicant]
Sriram et al., “Targeted cleavage of hepatitis E virus 3′ end RNA mediated by hammerhead ribozymes inhibits viral RNA replication”,
[cited by applicant]
Strain, “Crushing Cancer's Defenses: Vaccine approval offers hope while other armies muster,”
[cited by applicant]
Topalian et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,”
[cited by applicant]
Topalian et al., “Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity,”
[cited by applicant]
Ulmer et al., “RNA-based vaccines,”
[cited by applicant]
Vanham and Van Gulck, “Can immunotherapy be useful as a ‘functional cure’ for infection with Human Immunodeficiency Virus-1?”
[cited by applicant]
Verbeke et al., “Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells,”
[cited by applicant]
Vezys et al., “4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection”,
[cited by applicant]
Vogelzang and Agarwal, “Development of novel immune inteventions for genito-urinary cancers”, In: Cancer Vaccines. Editors: Adrian Bot, Mihail Obrocea, Francesco M. marincola, CRC Press, pp. 25-43, 2011.
[cited by applicant]
Wang et al., “mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma,”
[cited by applicant]